CYCLERION THERAPEUTICS, INC. Research and Development Expense
CYCLERION THERAPEUTICS, INC. (CYCN) reported Research and Development Expense of $730.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-04
- CYCLERION THERAPEUTICS, INC. research and development expense for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- CYCLERION THERAPEUTICS, INC. research and development expense for the quarter ending 2026-03-31 was $730.00K, a 1927.78% increase year-over-year.
- CYCLERION THERAPEUTICS, INC. research and development expense for the quarter ending 2025-12-31 was $519.00K, a 826.79% increase year-over-year.
- CYCLERION THERAPEUTICS, INC. research and development expense for the quarter ending 2025-09-30 was $348.00K, a 329.63% increase year-over-year.
- CYCLERION THERAPEUTICS, INC. research and development expense for fiscal 2023 was $1.51M, a 74.66% decline from fiscal 2022.
- CYCLERION THERAPEUTICS, INC. research and development expense for fiscal 2022 was $5.98M, a 84.11% decline from fiscal 2021.
- CYCLERION THERAPEUTICS, INC. research and development expense for fiscal 2021 was $37.64M, a 33.29% decline from fiscal 2020.
- CYCLERION THERAPEUTICS, INC. research and development expense for fiscal 2020 was $56.41M, a 40.70% decline from fiscal 2019.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − S-4/A 3 month · filed 2026-08-04 | $730.00K 10-Q · filed 2026-08-04 | $1.25M derived: sum of 3 quarters · filed 2026-08-04 | $1.60M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | $730.00K S-4/A · filed 2026-07-22 | $1.25M derived: sum of 2 quarters · filed 2026-07-22 | $1.60M derived: sum of 3 quarters · filed 2026-07-22 | $1.65M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | $519.00K derived: S-4/A 12 month − 10-Q 9 month · filed 2026-07-22 | $867.00K derived: sum of 2 quarters · filed 2026-07-22 | $923.00K derived: sum of 3 quarters · filed 2026-08-04 | $959.00K S-4/A · filed 2026-07-22 | ||||
| 2025-09-30 | $348.00K 10-Q · filed 2025-11-12 | $404.00K derived: sum of 2 quarters · filed 2026-08-04 | $440.00K 10-Q · filed 2025-11-12 | $496.00K derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | $56.00K 10-Q · filed 2026-08-04 | $92.00K 10-Q · filed 2026-08-04 | $148.00K derived: sum of 3 quarters · filed 2026-08-04 | $229.00K derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | $36.00K S-4/A · filed 2026-07-22 | $92.00K derived: sum of 2 quarters · filed 2026-07-22 | $173.00K derived: sum of 3 quarters · filed 2026-07-22 | $278.00K derived: sum of 4 quarters · filed 2026-07-22 | ||||
| 2024-12-31 | $56.00K derived: S-4/A 12 month − 10-Q 9 month · filed 2026-07-22 | $137.00K derived: sum of 2 quarters · filed 2026-07-22 | $242.00K derived: sum of 3 quarters · filed 2026-07-22 | $286.00K S-4/A · filed 2026-07-22 | ||||
| 2024-09-30 | $81.00K 10-Q · filed 2025-11-12 | $186.00K derived: sum of 2 quarters · filed 2025-11-12 | $230.00K 10-Q · filed 2025-11-12 | $254.00K derived: sum of 4 quarters · filed 2025-11-12 | ||||
| 2024-06-30 | $105.00K 10-Q · filed 2025-08-05 | $149.00K 10-Q · filed 2025-08-05 | $173.00K derived: sum of 3 quarters · filed 2025-11-12 | $753.00K derived: sum of 4 quarters · filed 2025-11-12 | ||||
| 2024-03-31 | $44.00K 10-Q · filed 2025-05-06 | $68.00K derived: sum of 2 quarters · filed 2025-11-12 | $648.00K derived: sum of 3 quarters · filed 2025-11-12 | $987.00K derived: sum of 4 quarters · filed 2025-11-12 | ||||
| 2023-12-31 | $24.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2025-11-12 | $604.00K derived: sum of 2 quarters · filed 2025-11-12 | $943.00K derived: sum of 3 quarters · filed 2025-11-12 | $1.51M 10-K/A · filed 2025-11-12 | ||||
| 2023-09-30 | $580.00K 10-Q · filed 2024-11-14 | $919.00K derived: sum of 2 quarters · filed 2024-11-14 | $1.49M 10-Q · filed 2024-11-14 | $2.67M derived: sum of 4 quarters · filed 2024-11-14 | ||||
| 2023-06-30 | $339.00K 10-Q · filed 2024-08-07 | $886.00K 10-Q · filed 2023-07-28 | $911.00K 10-Q · filed 2024-08-07 | $4.66M 10-Q · filed 2023-07-28 | $2.09M derived: sum of 3 quarters · filed 2024-08-07 | $3.50M derived: sum of 4 quarters · filed 2024-08-07 | ||
| 2023-03-31 | $572.00K 10-Q · filed 2024-05-07 | $3.77M 10-Q · filed 2023-05-12 | $1.75M derived: sum of 2 quarters · filed 2024-05-07 | $3.16M derived: sum of 3 quarters · filed 2024-05-07 | $13.38M derived: sum of 4 quarters · filed 2024-05-07 | |||
| 2022-12-31 | $1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $2.59M derived: sum of 2 quarters · filed 2024-03-05 | $12.81M derived: sum of 3 quarters · filed 2024-03-05 | $5.98M 10-K · filed 2024-03-05 | $31.49M 10-K · filed 2023-03-22 | |||
| 2022-09-30 | $1.41M 10-Q · filed 2023-11-13 | $7.08M 10-Q · filed 2022-11-03 | $11.63M derived: sum of 2 quarters · filed 2023-11-13 | $4.80M 10-Q · filed 2023-11-13 | $27.04M 10-Q · filed 2022-11-03 | $31.83M derived: sum of 4 quarters · filed 2023-11-13 | ||
| 2022-06-30 | $10.22M 10-Q · filed 2023-07-28 | $19.96M 10-Q · filed 2023-07-28 | $30.42M derived: sum of 3 quarters · filed 2023-07-28 | $37.45M derived: sum of 4 quarters · filed 2023-07-28 | ||||
| 2022-03-31 | $9.74M 10-Q · filed 2023-05-12 | $20.20M derived: sum of 2 quarters · filed 2023-05-12 | $27.23M derived: sum of 3 quarters · filed 2023-05-12 | $39.29M derived: sum of 4 quarters · filed 2023-05-12 | ||||
| 2021-12-31 | $10.46M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $17.49M derived: sum of 2 quarters · filed 2023-03-22 | $29.54M derived: sum of 3 quarters · filed 2023-03-22 | $37.64M 10-K · filed 2023-03-22 | ||||
| 2021-09-30 | $7.03M 10-Q · filed 2022-11-03 | $19.09M derived: sum of 2 quarters · filed 2022-11-03 | $27.18M 10-Q · filed 2022-11-03 | $39.27M derived: sum of 4 quarters · filed 2022-11-03 | ||||
| 2021-06-30 | $12.05M 10-Q · filed 2022-08-09 | $20.15M 10-Q · filed 2022-08-09 | $32.24M derived: sum of 3 quarters · filed 2022-08-09 | $45.94M derived: sum of 4 quarters · filed 2022-08-09 | ||||
| 2021-03-31 | $8.09M 10-Q · filed 2022-05-04 | $20.18M derived: sum of 2 quarters · filed 2022-05-04 | $33.89M derived: sum of 3 quarters · filed 2022-05-04 | $47.68M derived: sum of 4 quarters · filed 2022-05-04 | ||||
| 2020-12-31 | $12.09M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $25.80M derived: sum of 2 quarters · filed 2022-02-24 | $39.59M derived: sum of 3 quarters · filed 2022-02-24 | $56.41M 10-K · filed 2022-02-24 | ||||
| 2020-09-30 | $13.70M 10-Q · filed 2021-11-09 | $27.50M derived: sum of 2 quarters · filed 2021-11-09 | $44.32M 10-Q · filed 2021-11-09 | $65.00M derived: sum of 4 quarters · filed 2021-11-09 | ||||
| 2020-06-30 | $13.79M 10-Q · filed 2021-07-29 | $30.62M 10-Q · filed 2021-07-29 | $51.30M derived: sum of 3 quarters · filed 2021-07-29 | $73.60M derived: sum of 4 quarters · filed 2021-07-29 | ||||
| 2020-03-31 | $16.82M 10-Q · filed 2021-04-30 | $37.51M derived: sum of 2 quarters · filed 2021-04-30 | $59.80M derived: sum of 3 quarters · filed 2021-04-30 | $85.56M derived: sum of 4 quarters · filed 2021-04-30 | ||||
| 2019-12-31 | $20.68M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $42.98M derived: sum of 2 quarters · filed 2021-02-25 | $68.74M derived: sum of 3 quarters · filed 2021-02-25 | $95.14M 10-K · filed 2021-02-25 | ||||
| 2019-09-30 | $22.30M 10-Q · filed 2020-11-05 | $48.05M derived: sum of 2 quarters · filed 2020-11-05 | $74.46M 10-Q · filed 2020-11-05 | $96.91M derived: sum of 4 quarters · filed 2020-11-05 | ||||
| 2019-06-30 | $25.76M 10-Q · filed 2020-08-03 | $52.16M 10-Q · filed 2020-08-03 | $74.61M derived: sum of 3 quarters · filed 2020-08-03 | $96.11M derived: sum of 4 quarters · filed 2020-08-03 | ||||
| 2019-03-31 | $26.40M 10-Q · filed 2020-05-04 | $48.86M derived: sum of 2 quarters · filed 2020-05-04 | $70.36M derived: sum of 3 quarters · filed 2020-05-04 | $92.61M derived: sum of 4 quarters · filed 2020-05-04 | ||||
| 2018-12-31 | $22.45M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $43.95M derived: sum of 2 quarters · filed 2020-03-12 | $66.20M derived: sum of 3 quarters · filed 2020-03-12 | $87.72M 10-K · filed 2020-03-12 | ||||
| 2018-09-30 | $21.50M 10-Q · filed 2019-11-12 | $43.75M derived: sum of 2 quarters · filed 2019-11-12 | $65.26M 10-Q · filed 2019-11-12 | |||||
| 2018-06-30 | $22.25M 10-Q · filed 2019-08-12 | $43.77M 10-Q · filed 2019-08-12 | ||||||
| 2018-03-31 | $21.51M 10-Q · filed 2019-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |